VBI Vaccines Inc., formerly Paulson Capital Corp., is a biopharmaceutical company. It is developing technologies that seek to expand vaccine protection in large markets. VBI’s eVLP vaccine platform allows for the design of enveloped (e) virus-like particle (VLP) vaccines that closely mimic the target virus. VBI’s Liquid Particle Vaccines (LPV) technology enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating or elevated temperatures. It is developing a prophylactic vaccine to prevent Cytomegalovirus (CMV) infection. The company’s lead eVLP asset is CMV vaccine; VBI has initiated work for GMP manufacturing of its CMV candidate for use in formal preclinical and Phase I trials. Its second platform is a thermostable technology that enables the development of vaccines and biologics that can withstand storage or shipment at constantly fluctuating temperatures. Effective July 25, 2014, Paulson Capital Corp merged with VBI Vaccines.